BioSpace News Archive

I-Mab (the “Company”) (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in its China phase 2 trial of lemzoparlimab in combination with the PD-1 antibody toripalimab (TUOYI®) in patients with advanced solid tumors.

BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced today the dose administration for the first patient in Canada in partnership with the University Health Network in a Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with advanced Parkinson’s disease.

Incyte (Nasdaq:INCY) announced today that it has scheduled its fourth quarter and year-end 2021 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, February 8, 2022.

AffaMed Therapeutics, licensee of DEXTENZA ® in Certain Asian Markets, Doses Their First Patient in Clinical Trial Evaluating the Safety and Efficacy of DEXTENZA ® in China in Cataract Surgery Patients.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the enrollment of the first patient in the SHIELD (Screening for HIgh-frEquency maLignant Disease) LUNG study, a nearly 10,000-patient prospective, registrational study to evaluate the performance of its next-generation Guardant SHIELD blood test in detecting lung cancer in high-risk individuals ages 50-80.

Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a company focused on the growing field of cancer metabolism-based therapeutics, today announced the ongoing successful enrollment rate of its Phase 2 clinical trial for CPI-613® (devimistat) in combination with gemcitabine and cisplatin in patients with biliary tract cancer.

LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers (gamma delta bsTCEs) to transform the treatment of cancer, today announced it will present preclinical data on its Gammabody™ platform and data on its lead solid tumor Gammabody™ LAVA-1207.

Nanalysis Scientific Corp. is pleased to announce that it has entered into a letter of intent to acquire QUAD Systems AG, a Zurich-based Nuclear Magnetic Resonance company focused on high-field NMR for pharmaceutical and other vertical markets.

Endosane Pharmaceuticals and the University of California Irvine have agreed to investigate the efficacy of two innovative compounds for the treatment of post-traumatic stress disorder through a series of preclinical studies.

OSI Systems, Inc. announced that its Optoelectronics and Manufacturing division has received an order for approximately $5 million to provide electronic components to a leading X-ray imaging original equipment manufacturer.